As global oncology races toward next-generation therapies, Avammune Therapeutics is betting on affordable, orally administered immunotherap...

A rare Bundibugyo virus outbreak in Congo, with over 200 deaths, lacks specific treatments or vaccines, complicating response efforts. Whil...

A new Ebola vaccine developed by Russian scientists shows promise against the current outbreak strain in the Democratic Republic of Congo. ...

Given the latest news flow from the Gulf region, the probability is high that we might once again see the bulls attempting a comeback. As u...

Scientists in Chile developed antibodies that successfully neutralised the deadly Andes hantavirus in lab and animal studies, raising hopes...

India’s cancer treatment landscape is seeing a shift as lower-cost immunotherapy drugs developed in China and marketed through Indian partn...

Hantavirus Andes strain update: A deadly Andes strain hantavirus outbreak linked to the MV Hondius cruise ship has resulted in three deaths...

Lord's Mark Industries Ltd. has secured Central Licensing Authority approval for its LordsMed HIV 1&2 Self Test, becoming one of nine globa...

Bharat Biotech said the “comprehensive” study has demonstrated multiple benefits of its vaccine, including long-term immune response, cell-...

The findings are particularly important when considering administering third booster dose aiming to elicit robust antibody response and hel...

The finding has implications for the ability of new variants to reinfect people who contracted earlier versions of the virus.

The study also found, however, that a critical component of the immune system known as T cells showed a more enhanced response in those who...

The study on the immune response to Covishield was carried out by researchers from New Delhi's CSIR-Institute of Genomics and Integrative B...

The study, which has not been peer-reviewed and was pre-printed by medRxiv on February 1, reveals that the antibody response generated by t...

"Our results suggest that the COVID-19 virus may awaken an antibody response that existed in humans prior to our current pandemic, meaning ...

The findings also suggest the loss of antibodies was slower in 18-24 year-olds compared to those aged 75 and over.

Patients who recover from the novel coronavirus may have an antibody response that makes them immune to the deadly virus only for a few mon...